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Introduction: A large proportion of the cardiovascular disease (CVD) burden can potentially 
be prevented by primary prevention programs addressing major causal risk factors. A   Web-based 
health risk assessment (HRA) with tailored feedback for individual health promotion is a 
promising strategy. We evaluated the effect on CVD risk of such a program among employees 
of a Dutch worksite.
Methods: We conducted a prospective follow-up study among 368 employees who voluntarily 
participated in a Web-based HRA program at a single Dutch worksite in 2008. The program 
included a multicomponent HRA through a Web-based electronic questionnaire, biometrics, 
and laboratory evaluation. The results were combined with health behavior change theory to 
generate tailored motivational and educational health advice. On request, a health counseling 
session with the program physician was available. Follow-up data on CVD risk were collected 
1 year after initial participation. The primary outcome was a change in Framingham CVD risk 
at 6 months relative to baseline. We checked for a possible background effect of an increased 
health consciousness as a consequence of program introduction at the worksite by comparing 
baseline measurements of early program participants with baseline measurements of participants 
who completed the program 6 months later.
Results: A total of 176 employees completed follow-up measurements after a mean of 7 months. 
There was a graded relation between CVD risk changes and baseline risk, with a relative reduction 
of 17.9% (P = 0.001) in the high-risk category (baseline CVD risk $20%). Changes were not 
explained by additional health counseling, medication, or an increase in health consciousness 
within the company.
Conclusions: Voluntary participation in a Web-based HRA with tailored feedback at the 
worksite reduced CVD risk by nearly 18% among participants at high CVD risk and by nearly 5% 
among all participants. Web-based HRA could improve CVD risk in similar populations. Future 
research should focus on the persistence of the effects underlying the CVD risk reduction.
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Introduction
Cardiovascular disease (CVD) represents the majority of the chronic disease burden 
in Europe.1 Major causal risk factors include an unhealthy diet, physical inactivity, 
smoking, high blood pressure, dyslipidemia, high plasma glucose, and being 
overweight.2,3 The CVD burden could be greatly reduced by adequately addressing 
these risk factors.4 A health risk assessment (HRA) is one of the most widely used 
strategies in the primary prevention of CVD. The worksite has been proposed as a 
suitable platform for such programs, with the advantage of cost savings, the creation 





The traditional HRA screened for risk factors to produce 
feedback that predominantly contained information on the 
assessed risk.7 However, reviews of the literature did not 
always support the effectiveness of the traditional HRA.7,8 
It was theorized that HRA with feedback that merely contains 
risk information would be insufficient to promote health.9 
The impact of the traditional HRA also remained unsatisfying 
as a consequence of suboptimal delivery due to resource 
constraints, limited access to high-risk populations, and no 
uniformity.7,8 It was acknowledged that the impact of HRA 
programs could be enhanced by Web-based delivery of the 
HRA, with incorporation of tailored health advice, aiming 
to reduce disease risk.9–12
In the present study we evaluated CVD risk changes 
among employees who voluntarily participated in a 
Web-based HRA including tailored feedback that was 
offered to them by their employer as part of a worksite 
health   management program. The HRA was designed to 
collect data that are necessary to screen for the risk of a 
number of preventable diseases, including CVD, and provide 
  tailored feedback in order to educate, motivate, and empower 
  participants in CVD risk reduction. The primary aim was to 
measure whether CVD risk was improved after participation 
in the program at a Dutch worksite.
Materials and methods
Study setting, design, and flow
We conducted a prospective follow-up study among 
employees of a Dutch company in the services sector who 
voluntarily completed a Web-based HRA including tailored 
feedback. The HRA was applied as part of the worksite 
health management program in the company in 2008. During 
this period, 2149 employees were invited to complete the 
HRA. Email invitations were sent by the human resources 
  department, with a single reminder after 2 weeks. Employees 
were informed that participation was voluntary, at no cost, 
that all personal data would be treated confidentially, and 
that no results would be shared with their employer or any 
other party. Before invitation, employees were divided into 
an early (n = 1108) and late (n = 1041) invitation group, 
based on date of birth (Figure 1).
The early invitation group was invited immediately to 
participate in the HRA. Employees of the early invitation 
group who completed the HRA and received their tailored 
health advice were re-invited for follow-up measurements 
6 months after completion. They were not informed about 
follow-up measurements until the moment of re-invitation. 
Employees of the late invitation group were invited 6 months 
after the early invitation group was invited. Their baseline 
measurements were used to assess potential changes in CVD 
risk factor levels as a consequence of company-wide changes 
in health consciousness. If present, these temporal changes 
would have led to overestimation of the effects of the HRA 
program. The study was approved by the Medical Ethics 
Committee of the Academic Medical Center in Amsterdam, 
the Netherlands.
study intervention: web-based HRA  
with tailored feedback
The studied program consisted of i) a multicomponent 
Web-based HRA and ii) individually tailored health advice, 
presented to participants as a Web-based health action plan. 
The HRA included i) a Web-based electronic questionnaire, 
ii) a biometric evaluation, and iii) a laboratory evaluation, 
targeting chronic disease risk, including CVD.   Biometrics 
and collection of samples for laboratory evaluation were 
  conducted by a licensed occupational health services 
provider. Results of the assessment were translated into low-, 
intermediate-, or high-risk profiles for the targeted disorders. 
By a computer-based combination of the risk profiles with 
health-behavior concepts, individually tailored health advice 
was generated. Underlying health behavior concepts include 
the transtheoretical model,13 protection motivation theory,14 
and social cognitive theory.15 The Web-based health action 
plans addressed health behavior (physical activity, smoking 
cessation, alcohol intake, dietary habits) and included referral 
for further evaluation and treatment for those at high CVD 
risk. Risk factor cutoff values were based on the European 
and Dutch guidelines for cardiovascular risk management.16,17 
On request, participants could schedule a 30-minute health 
counseling session with the program physician.
Baseline measurements
In the present study, all early and late participants completed 
the Web-based electronic questionnaire as part of their HRA. 
The questionnaire included sociodemographics, family history 
of CVD, personal medical history, current treatment, and 
  current lifestyle. Physical activity was measured with the Dutch 
version of the International Physical Activity Questionnaire.18 
Dietary habits and alcohol consumption were measured 
according to the standard nutrition and alcohol consump-
tion questionnaire of the Dutch Municipal Health   Service.19 
Smoking behavior was measured with the Dutch Expert Center 
on Tobacco Control questionnaire.20 The questionnaire also 
addressed the health behavior change stage according to the 
transtheoretical model.13 This model suggests that changes in Vascular Health and Risk Management 2011:7
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Figure 1 Study flow.
Notes: The HRA program was applied as part of the worksite health management program in a Dutch company worksite in 2008. During this period 2149 employees were 
invited to complete the HRA. employees were divided by day and month of birth in an early and late invitation group. early invitees who participated in the HRA program 
were invited for follow-up measurements, six months after the initial program invitation. At that same time the late invitation group was invited for their initial participation. 
The primary outcome was the change in CVD risk between baseline and follow-up among 176 early participants. To account for time trends, baseline variables between early 
and late participants were compared. nonresponse bias was checked by comparing baseline values of 176 early participants who attended follow-up with 192 who did not.
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health behavior appear in six phases from precontemplation 
(not intending to take action in the foreseeable future), contem-
plation (intending to change in the next 6 months), preparation 
(intending to take action in the next month), action (have made 
specific overt lifestyle modifications within the past 6 months), 
to maintenance (working to prevent relapse) and termination 
(is sure not to return to an old unhealthy habit). The health 
advice contained in the health plans was computer tailored to 
the stage of change of the participant.
All early and late participants in the HRA also visited 
the worksite occupational health service for measurement 
of height, weight, waist circumference, and blood pressure. 
During the visit, nonfasting blood and urine samples were 
  collected for analysis of total cholesterol, low-density 
lipoprotein (LDL)-cholesterol, high-density lipoprotein 
(HDL)-cholesterol, triglycerides, glucose, creatinin, and 
urinary albumin to creatinin ratio. Blood pressure was 
measured twice with a 2-minute interval on the left arm using 
an automated device (Omron M4, Omron Corp, Tokyo, Japan) 
after the subject had been sitting quietly for at least 5 minutes. 
Height was measured to the nearest centimeter and weight to 
the nearest 0.5 kilogram, with subjects wearing indoor cloth-
ing, without shoes, and with emptied pockets. A correction of 





was measured with a centimeter tape, in the middle between 
the pelvic edge and lower rib. Collected samples were sent 
to a certified laboratory. Serum was centrifuged at 3000 G 
for 10 minutes prior to transportation. All procedures were 
performed by trained nurses. The blood sample was analyzed 
using enzymatic kits (Roche Diagnostics).
Follow-up measurements
The early participants were re-invited for follow-up 
measurements 6 months after they completed their baseline 
HRA and received their tailored health advice. Invitations 
for follow-up measurements were sent by email with 
one reminder, by the study physician of the Academic 
Medical Center, University of Amsterdam, Amsterdam, 
the Netherlands. A follow-up visit was scheduled for 
measurements of weight, waist circumference, blood 
pressure, nonfasting total cholesterol, LDL-cholesterol, 
HDL-cholesterol, and triglycerides. The employees were 
informed of their follow-up results by the study physician.
Outcomes and data analysis
The primary outcome was the percentage change in 
Framingham score at 6 months relative to baseline. 
The Framingham score estimates CVD mortality and mor-
bidity risk by combining age, sex, blood pressure, hyperten-
sion treatment status, total cholesterol, HDL-cholesterol, 
smoking, and diabetes status.21 CVD risk changes were also 
studied in low-, intermediate-, and high-risk subgroups, 
defined as CVD risk ,10%, $10%–20%, and $20%. 
  Secondary outcomes were changes in single risk factor levels 
at 6 months relative to baseline. For comparisons between 
baseline and follow-up, paired t-tests were used for continu-
ous variables and McNemar’s test for dichotomous variables. 
Analysis of variance was used to study CVD risk changes 
over the three CVD risk subgroups. Participants with known 
CVD (coronary heart disease, myocardial infarction, periph-
eral arterial disease, heart failure, and stroke) were excluded 
from the primary outcome analysis. In addition, changes 
in CVD risk and single risk factor levels were compared 
between participants who had a voluntary health counseling 
session additional to their Web-based health plan and those 
who did not, using Chi-squared tests. Nonresponse bias was 
checked by comparing differences in baseline values between 
early participants who attended for follow-up measurements 
and those who did not, using unpaired t-test for continuous 
variables and Chi-squared tests for dichotomous variables. 
These comparisons were adjusted for age and gender 
  differences by linear and logistic regression analysis. Finally, 
to account for temporal trends in health consciousness as 
a consequence of program introduction at the worksite, 
baseline variables between early and late participants were 
compared. In these analyses, unpaired t-tests were used for 
continuous variables and Chi-squared tests for dichotomous 
variables. Data were analyzed using SPSS Version 17 (SPSS 
Inc., Chicago, IL, USA) for Windows.
Results
Of the 1108 early invited employees, 368 (33%) partici  pated 
in the Web-based HRA program, compared with 404 (39%) 
of the 1041 late invited employees. Of the early participant 
group of 368 employees, 176 (48%) attended for follow-up 
measurements at the mean follow-up time of 7 months. 
Table 1 summarizes all baseline values. Early participants 
who attended follow-up were older than those who did 
not (46 vs 43 years, P , 0.001), had a higher CVD risk 
(10.2% vs 7.5%, P , 0.001), and had a higher systolic 
blood pressure (134.6 vs 131.0 mm Hg, P = 0.049). After 
adjustment for sex and age, there were no differences in 
health characteristics between employees who attended 
for follow-up measurements and those who did not attend 
(see adjusted P-values in Table 1).
Table 2 shows the change in CVD risk at follow-up 
relative to baseline. Among employees with a baseline risk 
of $20%, CVD risk decreased 17.9% (95%   confidence 
  interval [CI]: −27.7% to −8.2%, P = 0.001). Among 
  employees with a baseline CVD risk of $10% to 20%, CVD 
risk decreased 4.4% (95% CI −10.6% to 1.7%, P = 0.155). 
Among employees with a CVD risk ,10%, there was a 
decrease in CVD risk of 2.5% (95% CI −8.1% to 3.1%, 
P = 0.376). The linear term in analysis of variance of the rela-
tive change in CVD risk score was statistically significantly 
different between employees in the three CVD risk categories 
(P = 0.014).
Among the follow-up attendees, 49 employees requested 
a voluntary health counseling session with the program 
physician after receiving their health plan, whereas 
127 employees did not. Seven employees were referred 
to their primary care physician for treatment of high 
blood pressure. In two cases the primary care physician 
started pharmacologic treatment, and in five cases an 
existing treatment regimen was changed. The total number 
of employees on blood pressure medication increased 
nonsignificantly from 14 (8%) at baseline to 16 (9%) at 
follow-up. Treatment with statins was not initiated for any Vascular Health and Risk Management 2011:7
Table 1 Baseline characteristics
  Early participants  
(n = 368)















Mean age (years) 46 ± 7.8 43 ± 7.4 ,0.001 – 45 ± 7.8 44.5 ± 8.45 0.966
Male sex 142 (81%) 154 (80%) 0.909 – 296 (80%) 327 (81%) 0.859
education
  Low 21 (12%) 16 (8%) 0.311 – 37 (10%) 43 (11%) 0.918
  Middle 49 (28%) 45 (24%) 94 (26%) 103 (25%)
  High 106 (60%) 131 (68%) 237 (64%) 258 (64%)
History of CVD 6 (3%) 4 (2%) 0.529 0.810 10 (3%) 6 (1%) 0.230
Current medication therapy  
for hypertension
14 (8%) 15 (8%) 0.960 0.411 29 (8%) 26 (7%) 0.436
Current statin use 8 (5%) 11 (6%) 0.608 0.121 19 (5%) 12 (3%) 0.121
Current diabetes medication 3 (2%) 4 (2%) 1.000 0.557 7 (2%) 4 (1%) 0.286
Current smoking 27 (15%) 32 (17%) 0.729 0.729 59 (16%) 80 (20%) 0.173
systolic BP (mm Hg) 134.6 ± 16.64 131.0 ± 15.83  0.049 0.176 132.9 ± 16.29 129.6 ± 16.66  0.006
Diastolic BP (mm Hg) 81.3 ± 10.90 79.8 ± 10.56  0.162 0.502 80.5 ± 10.73  78.0 ± 10.24 0.001
systolic BP $140 mm Hg 60 (34%) 49 (26%) 0.072 0.225 106 (29%) 109 (27%) 0.295
Diastolic BP $90 mm Hg 38 (22%) 24 (13%) 0.020 0.114 62 (17%) 51 (13%) 0.097
Body mass index (kg/m2) 25.3 ± 3.37 25.3 ± 3.68  0.967 0.753 25.3 ± 3.53 25.6 ± 3.25 0.226
Waist circumference (cm) 92.7 ± 10.88 92.6 ± 10.31  0.946 0.698 92.7 ± 10.57 93.6 ± 10.42 0.209
Total cholesterol (mmol/L) 5.7 ± 1.00 5.6 ± 0.94  0.113 0.398 5.6 ± 0.97 5.7 ± 1.05 0.302
HDL (mmol/L) 1.4 ± 0.35 1.4 ± 0.37  0.484 0.215 1.4 ± 0.36 1.5 ± 0.60 0.080
LDL (mmol/L) 3.6 ± 0.86 3.5 ± 0.89  0.063 0.178 3.6 ± 0.88 3.5 ± 0.91 0.691
Triglycerides (mmol/L) 1.62 ± 0.98 1.5 ± 0.82  0.238 0.448 1.6 ± 0.90 1.7 ± 1.30 0.011
Framingham 10-year CVD  
risk score (%)c
10.2 ± 8.55 7.5 ± 6.65 ,0.001 0.182 8.8 ± 7.72 8.7 ± 7.19 0.964
Notes: Values are expressed as mean ± sD or number of participants (%). aP for difference in baseline value between early participants with and without follow-up for 
selection analysis. Analyses for differences in baseline systolic and diastolic blood pressure, body mass index, waist circumference, total cholesterol, HDL, LDL, triglycerides, 
and Framingham scores were adjusted for age and sex using linear regression with the variable of interest as dependent variable and age, sex, and attending for follow-up 
measurements as covariates. Analyses for differences in history of CVD, current medication for hypertension, current statin use, current diabetes medication, current 
smoking, systolic blood pressure $140mm Hg, and diastolic blood pressure $90 mm Hg were adjusted for age and sex using logistic regression with the variable of interest 
as dependent variable and age, sex and attending for follow-up measurements as covariates. bP for difference in baseline value between early and late participants for time 
trend analysis. cParticipants with a known history of CVD were excluded from the Framingham risk analysis.
Abbreviations: BP, blood pressure; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; sD, standard deviation.
Table 2 Changes in cardiovascular disease (CVD) risk among employees who voluntarily participated in the Web-based health risk 
assessment and attended follow-up measurements at a mean of 7 months
  N CVD risk (%) 
at baseline
CVD risk (%) 
at follow-up
Relative changea Pb Pc
CVD risk changes in all study participants 170d 10.2 ± 8.55   9.4 ± 7.97 −4.9 (−8.9 to −0.9) 0.017
CVD risk changes in high-, intermediate-, and low-risk categories:
  Framingham 10-year CVD risk $20% 21 28.4 ± 7.63 23.7 ± 10.61 −17.9 (−27.7 to −8.2) 0.001 0.014
  Framingham 10-year CVD risk $10% to ,20% 43 13.6 ± 2.74 13.0 ± 3.65 −4.4 (−10.6 to 1.7) 0.155
  Framingham 10-year CVD risk ,10% 106   5.2 ± 2.70   5.1 ± 3.29 −2.5 (−8.1 to 3.1) 0.376
Notes: Values are expressed as mean CVD risk score percentage ± standard deviation and mean relative differences in percentages. aRelative difference in value between 
follow-up and baseline (95% confidence interval); bP for effects within category; cP from linear term in analysis of variance. dsix participants with a known history of CVD 
were excluded from the analysis.
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employee. There were no statistically significant differences 
in changes in Framingham risk between employees who had 
health counseling and those who did not.
Table 3 summarizes the changes in single risk   factor levels. 
Systolic blood pressure was reduced by 5 mm Hg (P , 0.001), 
HDL-cholesterol increased by 0.1 mmol/L (P , 0.001), and 
waist circumference reduced by 2 cm (P , 0.001). Changes 
in number of smokers, body mass index, and diastolic blood 
pressure were not statistically significant. There was a slight 





0.2 mmol/L (P , 0.001) and triglycerides with 0.1 mmol/L 
(P = 0.025).
Early and late participants were similar in age, sex, 
education, ethnicity, medical history, and medication use 
at baseline (see right panel of Table 1). Baseline systolic 
blood pressure of late participants was 3.3 mm Hg lower 
than that of early participants, and diastolic blood pressure 
was 2.5 mm Hg lower. Framingham risk scores, however, 
were similar between early and late participants.
Discussion
We observed a significant decrease in CVD morbidity and 
mortality risk among employees at a single Dutch worksite 
who voluntarily completed a Web-based HRA and received 
tailored health advice, as measured by Framingham scores 
after 7 months. There was a graded relation between CVD 
risk reduction and baseline CVD risk. The decrease was 
highest among those at greatest risk, with a 17.9% relative 
reduction in the high-risk subgroup, and lower among those 
at intermediate and low risk.
The reduction in CVD risk was mainly due to reduced 
systolic blood pressure (−5.0 mm Hg reduction), whereas 
no beneficial effects were found for total cholesterol, 
triglycerides, and LDL-cholesterol. Because the observed 
beneficial changes were not explained by additional health 
counseling, referral to primary care physicians, or medication, 
and given that improvements in physical activity and diet can 
be effective in both reducing blood pressure and increasing 
HDL,22–25 we believe that the observed effect is explained by 
lifestyle improvements induced by the individualized advice 
that each participant received.
A number of systematic reviews showed that multicom-
ponent prevention programs delivered at the worksite reduced 
CVD risk factors.26–28 The greatest effect appeared in those at 
greatest risk, in accordance with our findings.26 Few studies 
used global CVD risk as an outcome measure for effectiveness 
of multicomponent risk factor intervention programs. These 
studies reported global risk reductions ranging from 2% to 
14%, which are consistent with our findings.29–33
The design of our study enabled us to check for temporal 
trends as a consequence of program introduction at the 
worksite. We found that mean systolic blood pressure and 
diastolic blood pressure were lower among late participants 
when compared with early participants. This suggests a 
background effect of an increased health consciousness 
within the company, possibly as a consequence of program 
introduction. However, the mean overall CVD risk score 
was similar in early and late participants. Moreover, the 
proportion of participants at high systolic or diastolic blood 
pressure was also not different in the two groups. Therefore, 
although a background effect cannot be ruled out completely, 
its magnitude is marginal.
Our study has several limitations. First, participation in 
the studied HRA program was voluntary, with participation 
rates of 33% among the early participants and 39% among 
the late participants. Studies that evaluated HRA or health 
promotion programs reported participation rates from 20% 
to 76%,34,35 with the general impression that females, older 
employees, and mainly the worried well were attracted.36 
Although the participation rate in this study was as expected, 
we cannot rule out that among nonparticipants in the HRA 
program there were employees with more or less favor-
able health characteristics. Furthermore, of the early par-
ticipants who were eligible for study   measurements, about 
half completed follow-up. However, after adjustment for 
  differences in age and gender, there were no differences 
Table 3 Changes in risk factors among employees who voluntarily participated in the Web-based health risk assessment and attended 
follow-up measurements at a mean of 7 months
  Follow-up attendees (n = 176) P
At baseline At follow-up Changea
Current smoking 27 (15%) 22 (13%) −5 – 0.060
systolic blood pressure (mm Hg) 134.6 ± 16.64 129.6 ± 14.93 −5.0 (−6.8 to −3.3) ,0.001
Diastolic blood pressure (mm Hg) 81.3 ± 10.90 81.1 ± 9.78 −0.2 (−1.3 to 0.8) 0.692
Body mass index (kg/m2) 25.3 ± 3.37 25.2 ± 3.38 −0.1 (−0.2 to 0.04) 0.161
Waist circumference (cm) 92.7 ± 10.88 90.7 ± 10.63 −2.0 (−2.7 to −1.4) ,0.001
Total cholesterol (mmol/L) 5.7 ± 0.99 5.9 ± 1.01 0.2 (0.1 to 0.3) 0.001
High-density lipoprotein (mmol/L) 1.4 ± 0.35 1.5 ± 0.37 0.1 (0.03 to 0.1) ,0.001
Low-density lipoprotein (mmol/L) 3.6 ± 0.86 3.6 ± 0.87  0.0 (−0.1 to 0.1) 0.971
Triglycerides (mmol/L) 1.6 ± 0.98 1.7 ± 0.95 0.1 (0.1 to 0.2) 0.025
Notes: Values are expressed as mean ± standard deviation or number of participants (%) and absolute change between baseline and follow-up. aAbsolute difference in value 
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between follow-up attendees and nonattendees. Therefore, 
we believe that the outcomes of our study were not skewed 
by selection and are valid among employees who voluntarily 
participated in the HRA program. Second, ideally, CVD risk 
in late participants would also have been measured 6 months 
before the beginning of their program. In this way their mea-
surements could have served as a rigorous control for early 
participants. Unfortunately, we were not able to do an early 
measurement in late participants.   Nevertheless, the absence 
of a clinically relevant background effect supports the conclu-
sion that the differences observed in the early participants can 
be attributed to participation in the program. Third, we did 
not have data on whether employees regularly visited their 
primary care physician outside the HRA   program. Although 
additional physician counseling after tailored feedback within 
the program did not influence Framingham risk, we cannot 
completely rule out that some improvements could be from 
usual primary care management and not from the HRA. 
Finally, participants in the program were predominantly 
well-educated male employees. Therefore, our findings may 
be applicable only to comparable populations. However, 
as the impact of the HRA program was proportional to the 
absolute level of CVD risk, the program may be more effec-
tive in other, less educated populations.
In summary, voluntary participation in a Web-based HRA 
with tailored feedback at the worksite reduced CVD   morbidity 
and mortality risk by nearly 18% among participants at high 
risk for CVD and by nearly 5% among all participants. It is 
important to note that this risk reduction is realized with an 
easy-to-replicate, low-cost, Web-based delivered program, 
mostly with motivational and educational health advice and 
without initiation of pharmacologic therapy. Future research 
should focus on the persistence of these effects.
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